Skip to main content

HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3)

This funding record is inactive. Please see the program website or contact the program sponsor to determine if this program is currently accepting applications or will open again in the future.

 
Catalog of Federal Domestic Assistance Number: 93.279
Sponsors
Appalachian Regional Commission, Center for Substance Abuse Treatment, Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, National Institute on Drug Abuse, National Institutes of Health, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services
Deadlines
Letter of Intent (Optional): Dec 10, 2016
Application: Jan 10, 2017
Contact

A list of agency contacts is available in the application instructions.

Purpose

This funding opportunity will support two-stage, multi-method research projects that inform community response and promote comprehensive, integrated approaches to prevent HIV and hepatitis C virus infection, along with associated comorbidities, such as hepatitis B virus infection and sexually transmitted diseases, among people who inject drugs in rural US communities.

The program's primary focus is opioid injection and its consequences. Projects should provide evidence of the effectiveness of community response models and best practices in responding to opioid injection epidemics that can be implemented by public health systems in similar rural communities in the United States.

Eligibility

Eligible applicants include:

  • Higher education institutions
  • Nonprofit organizations
  • For-profit businesses
  • Governments, including tribes and territories
  • Other public agencies

A detailed list of eligible applicants may be found in the application instructions.

Geographic coverage
Nationwide and U.S. Territories
Amount of funding

Award Ceiling:

  • Budgets for Phase 1 Exploratory/ Developmental (UG3) projects must not exceed $400,000 in direct costs for any year.
  • Budgets for Phase II (UH3) projects are not limited but must reflect the actual needs of the proposed project.
Total Funding Available: $6,500,000
Expected Number of Awards: Up to 10-UG3 awards and 8-UH3 awards
Project period: Up to 5 years
Application process

While not required, prospective applicants are asked to submit a letter of intent 30 days prior to the application due date. The preferred Letter of Intent submission method is by email to NIDALetterofIntent@mail.nih.gov. The letter may also be mailed to:

Office of Extramural Policy and Review
National Institute on Drug Abuse/NIH/DHHS
6001 Executive Boulevard, Suite 4243, MSC 9550
Bethesda, MD 20892-9550

Links to the full announcement and online application procedures are available through grants.gov.

Note: This opportunity is listed under a single Funding Opportunity Announcement Number, RFA-DA-17-014 , and a series of Catalog of Federal Domestic Assistance (CFDA) Numbers based on research area.

  • 93.270 - Adult Viral Hepatitis Prevention and Control
  • 93.279 - Drug Abuse and Addiction Research Programs
  • 93.941 - HIV Demonstration, Research, Public and Professional Education Projects
Tagged as
HIV and AIDS · Illicit drug use · Research methods and resources



For complete information about funding programs, including your application status, please contact funders directly. Summaries are provided for your convenience only. RHIhub does not take part in application processes or monitor application status.